Skip to main content
Premium Trial:

Request an Annual Quote

CLX Health, Quest Diagnostics Partnering to Provide COVID-19 Testing for Events, Travel

NEW YORK – CLX Health and Quest Diagnostics said Tuesday that they are collaborating to provide COVID-19 molecular testing for international travelers and attendees of live events.

Under the collaboration, individuals will be able to schedule testing appointments at Quest patient centers and retail partner locations using CLX's TrustAssure Global Testing Platform. Results will be provided within 48 hours in advance of an event or travel date.

Quest is the first national COVID-19 molecular testing provider to participate in the TrustAssure platform.

"We're excited to continue to build our global testing platform with Quest Diagnostics as a collaborator in the United States. Their national capabilities will provide American consumers access to testing in key markets across the country," Joseph Gonzalez, chief strategy officer for CLX Health, said in a statement. "We are committed to developing solutions to meet testing requirements and ensure a safe travel experience for our clients and their customers around the world."

"COVID-19 testing is a powerful tool for providing insights that can foster safer environments," said Cathy Doherty, senior VP and group executive, clinical franchise solutions and marketing, at Quest. "As COVID-19 restrictions are lifted around the country and world, our collaboration with TrustAssure will allow us to facilitate high-quality testing for individuals looking to get back to recreation and travel."

Financial and other terms of the agreement were not disclosed.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.